VIDEO: Bylvay improves pruritus, reduces serum bile acids in Alagille syndrome

WASHINGTON D.C. — In a Healio video exclusive, Ron Cooper, CEO of Albireo Pharma, highlighted positive top-line safety and efficacy results of Bylvay for the treatment of Alagille syndrome in patients from birth to early adulthood.In the double-blind, placebo-controlled phase 3 ASSERT trial, patients were randomized 2:1 to receive once-daily 120 g/kg Bylvay (odevixibat, Albireo), a potent, selective inhibitor of the ileal bile acid transporter, or placebo for 24 weeks. Bylvay was found to be well-tolerated and met its study endpoints of improved pruritus (P = .002) and fatigue as wellRead More